Outcomes
What were the main findings from the study?
- MICARDIS® significantly reduced proteinuria at 1 year when directly compared with losartan. The reduction in proteinuria from baseline was 29% for MICARDIS® and 20% for losartan (p<0.05).7
- Baseline levels of gyclosylated haemoglobin did not affect the change in proteinuria from baseline in either treatment groups.7
- Systolic and diastolic blood pressure were lowered to a similar extent by MICARDIS® and losartan therapy.7
- Used continuously, MICARDIS® may help to slow the progression of renal disease in patients with type 2 diabetes.
/Graph29.jpg "Click to enlarge")
/Graph30.jpg "Click to enlarge")
Calendar
Tools and Downloads
- Clinical Abstract Library
- Expert Interview Library
- ONTARGET® Results Webcast
- Free ONTARGET® Online Publication Download
- Cardiovascular Risk Guidelines
- Renin Angiotensin System in Cardiovascular Medicine Journal
My Alerts
You will shortly be able to create your own personal alerts service bringing the latest MICARDIS® news and updates direct to your inbox. Watch this space for more information.
